Stockwinners Market Radar for May 20, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:39 EDT NCR Corp. COO sells 102.3K shares of common stock - In a regulatory filing, NCR Corp disclosed that its COO Owen Sullivan sold 102.3K shares of common stock on May 19th in a total transaction size of $4.84M, reducing his stake by about 28%.

20:25 EDT SPDR Gold Shares holdings rise from 1,031.27MT to 1,037.09MT - This is the highest level of holdings since March 31st.

18:27 EDT Barrick Gold CEO: Copper is 20% of our business - In an interview on CNBC's Mad Money, Mark Bristow said Barrick has a significant presence in all the big copper regions around the world. According to Bristow, copper represents about 20% of the company's business.

17:49 EDT Gaming and Leisure Properties boosts dividend 3% to 67c per share - Gaming and Leisure Properties announced that the Company's Board of Directors declared the second quarter 2021 cash dividend of 67c per share of its common stock, an increase of 2c per share per quarter, or 3%. The dividend is payable on June 25 to shareholders of record on June 11.

17:39 EDT StoneCo announces up to $200M new share repurchase program - StoneCo announced that its board of directors, pursuant to written resolutions dated May 19, has authorized a share repurchase program, under which Stone may repurchase up to $200M in outstanding Class A common shares. This new share repurchase program is a replacement to the previous share repurchase program announced by Stone on May 13, 2019. Under the former program, Stone repurchased a total of 3,595,713 shares on an average price of $55.40 per share, with a total amount of $199.2M.

17:29 EDT Container Store CEO buys 20.5K shares of common stock - In a regulatory filing, Container Store disclosed that its CEO Satish Malhotra bought 25.5K shares of common stock on May 20th in a total transaction size of $251K, boosting his stake by about 41%.

17:19 EDT General Dynamics awarded on $110.15M Army order - General Dynamics and EXPAL will compete for each order of the $110.15M firm-fixed-price contract for the demilitarization and disposal of conventional ammunition. Bids were solicited via the internet with eight received. Work locations and funding will be determined with each order, with an estimated completion date of May 20, 2026. U.S. Army Contracting Command is the contracting activity.

17:07 EDT Shaw Communications shareholders approve plan for combination with Rogers - Shaw Communications announced that holders of its Class A Participating Shares and Class B Non-Voting Participating Shares have overwhelmingly voted in favour of the previously announced plan of arrangement for the proposed business combination with Rogers at the special meeting of Shaw's shareholders held on May 20. The completion of the arrangement requires the approval of at least two-thirds of the votes cast by the holders of the Class A Shares and Class B Shares at the Meeting, voting separately as a class, as well as majority of the minority approval of the Class A Shareholders and Class B Shareholders, each voting separately as a class. As of April 6for the Meeting, there was a total of 22,372,064 Class A Shares and 476,285,262 Class B Shares outstanding. Shaw will be seeking a final order from the Alberta Court of Queen's Bench on May 25 to approve the Arrangement. The transaction remains subject to other customary closing conditions. The Arrangement is expected to be completed in the first half of 2022. Rogers has exercised its right to require Shaw to redeem all of Shaw's issued and outstanding preferred shares (at the redemption price of $25.00 per share plus any accrued and unpaid dividends up to but excluding the redemption date) on June 30, 2021 in accordance with their terms. Shaw expects to provide notice of its intention to redeem the preferred shares to the registered holders thereof on May 28, 2021.

16:57 EDT CytoDyn names Antonio Migliarese as new CFO - CytoDyn announced the promotion of Antonio Migliarese to CFO of the company. Mr. Migliarese joined CytoDyn in January 2020, and previously served as Vice President, Corporate Controller.

16:48 EDT Oasis Petroleum raises FY21 volume guidance to 63.5-66.5 from 67.5-71.0 MBoepd - Oasis is updating its FY21 volume and CapEx guidance to reflect the Permian divestment. 2021 E&P CapEx is expected to be $205M-$220M, as incremental activity that was planned in the Permian is expected to shift into the Williston in 2H21.

16:35 EDT Larimar gets EMA PRIME designation to CTI-1601 for the treatment of FA - Larimar Therapeutics announced that the European Medicines Agency has granted Priority Medicines designation to CTI-1601 for the treatment of FA. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with FA who are unable to produce enough of this essential protein. The PRIME designation was based on positive data from Larimar's nonclinical studies and Phase 1 clinical program in patients with FA. As announced last week, pharmacodynamic data from this program showed that daily subcutaneous injections of CTI-1601 at doses of 50 mg or 100 mg resulted in frataxin levels in peripheral tissues or buccal cells, that were at or in excess of those that would be expected in phenotypically normal heterozygous carriers. Safety data from the program indicated that repeated subcutaneous injections of CTI-1601 were generally well tolerated at doses up to 100 mg administered daily for 13 days. "We are thrilled to receive this PRIME designation, which provides valuable regulatory benefits and important external validation for our Friedreich's ataxia program," said Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar. "Notably, we believe CTI-1601 is the only drug candidate to receive such a designation for the treatment of FA as well as the only clinical-stage candidate that we are aware of that is designed to address the root cause of the disease. We look forward to CTI-1601's continued clinical development and to the planned initiations of our Jive open label extension and pediatric multiple-ascending dose trials, which are expected in the second half of the year." The PRIME program is designed to enhance support for the development of medicines that target an unmet medical need. Through PRIME, the EMA offers early and proactive support to medicine developers to optimize the generation of robust data on a medicine's benefits and risks and enable accelerated assessment of medicines applications so that these medicines can reach patients earlier. To receive a PRIME designation, a product candidate must show its potential to benefit patients with unmet medical needs based on early clinical data or on compelling non-clinical data and tolerability data from initial clinical trials. For more information on the PRIME program visit the EMA website.

16:33 EDT IKONICS and Teresa Collins partner for product promotion and distribution - IKONICS will work together with Teresa Collins Studio, a worldwide brand in the creative crafts market. The companies agree to collaborate in the promotion of the Ikonart Custom Stencil Kit along with the Ikonart ancillary product line. Ikonart intends to use Teresa Collins' brand images, designs, prints and patterns to help both companies integrate further into larger distribution channels. The goal is to connect consumers to the Ikonart Smart Screen Stencil brand and expand sales.

16:31 EDT Opera receives Nasdaq notification of non-compliance - Opera Limited announced that it received a letter from the Nasdaq Stock Market on May 18, 2021, notifying the company that it is not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its annual report on Form 20-F for the fiscal year ended December 31, 2020. This notification has no immediate effect on the listing or trading of the company's shares.

16:22 EDT Palo Alto Networks jumps 5% to $360 after Q3 results beat, FY21 guidance raised

16:19 EDT Deckers Brands jumps 6% to $329.26 after Q4 results beat estimates

16:17 EDT Deckers Brands reports Q4 gross margin 53.2% vs. 51.5% a year ago

16:16 EDT Ares Management to acquire Black Creek Group - Ares Management announced that a subsidiary of Ares has entered into a definitive agreement to acquire 100% of Black Creek Group's U.S. real estate investment advisory and distribution business, a real estate investment management firm. "We are very pleased to enter into this strategic transaction with Black Creek, which further scales our real estate business, expands us into core / core-plus strategies and provides us with a leading non-traded REIT retail distribution platform," said Michael Arougheti, Chief Executive Officer and President of Ares. "We believe that this highly complementary combination will add meaningful revenue synergies for our real estate business as we offer new products to our existing investor base." "This acquisition presents an attractive opportunity to further enhance our team's capabilities and grow our leading global real estate equity and debt business to approximately $29 billion in assets under management with offices spanning across the U.S. and Europe," said Bill Benjamin, Partner and Head of the Ares Real Estate Group. "We are very excited to partner with senior management at Black Creek to offer new strategies, expand our sourcing networks and bolster execution. We have known and respected the team at Black Creek for many years and we believe there is a strong cultural alignment, which positions us for long-term success of our combined businesses." Upon closing, key members of the Black Creek leadership team will remain in place and become part of the Ares Real Estate Group, which is led by Bill Benjamin. The transaction consideration will include an upfront amount comprised of a combination of cash and Ares Operating Group Units in addition to a potential performance-based earnout payable in a combination of cash and Ares equity. The transaction is expected to be accretive to Ares' after-tax fee related earnings per share of Class A common stock and after-tax realized income per share of Class A common stock in the first year and a more meaningful driver of growth in earnings in the years ahead. The transaction is expected to close early in the third quarter of 2021 and is subject to customary closing conditions, including regulatory approvals.

16:15 EDT Palo Alto Networks CEO says 'great strength across our business' - "The work-from-home shift earlier in the year and recent cybersecurity issues have increased the focus on security. Coupled with good execution, this has driven great strength across our business, with Q3 billings growth accelerating to 27% year over year. In particular, we saw a number of customers make large commitments to Palo Alto Networks across our three major platforms," said Nikesh Arora, chairman and CEO of Palo Alto Networks. "We are pleased to be raising our guidance for fiscal year 2021 as we see these trends continuing into our fiscal fourth quarter, bolstering our confidence in our pipeline."

16:13 EDT Deckers Brands board approves increase of $750M to share repurchase plan

16:11 EDT Biogen receives GMP multi-product license for Switzerland facility - Biogen announced that its next generation manufacturing facility in Solothurn, Switzerland has received a good manufacturing practice, or GMP, multi-product license from the Swiss Agency for Therapeutic Products. The Solothurn facility combines Biogen's latest concepts for fed-batch cell culture technology and protein purification, enabling the large-scale production of biopharmaceuticals. With more than 500 employees, the highly modernized facility design consists of multiple bio-manufacturing cells, or BMCs, with site infrastructure in place to support future BMCs if needed. The GMP licensure is an important step in the readiness of the site, which enables the future submissions of product files to regulatory authorities. Notably, the site could support the manufacturing of aducanumab if approved, expanding on Biogen's existing capacity in Research Triangle Park, North Carolina, as well as the potential manufacturing of lecanemab and other biologic assets.

16:10 EDT Home Depot announces $20B share repurchase plan - The board of directors authorized a new $20B share repurchase program, replacing its previous authorization.

16:08 EDT Processa Pharmaceuticals doses first patient in PCS499 trial - Processa Pharmaceuticals announced it has dosed its first patient in the Processa trial to evaluate PCS499 in treating ulcerations in patients who have Necrobiosis Lipoidica, or NL. NL is a rare, chronic, idiopathic, granulomatous disease of collagen degeneration caused by a number of diverse pathophysiological changes in a patient. In approximately 30% of NL patients, an open ulcer forms that can have a significant impact on a patient's quality of life.

16:08 EDT Xperi's DTS integrates Cumulus Media into car infotainment platform - The company states: "DTS, a wholly owned subsidiary of Xperi Holding Corporation (XPER) and CUMULUS MEDIA (CMLS) announced the integration of CUMULUS MEDIA's network of radio stations into the DTS AutoStage connected car infotainment platform. DTS AutoStage is the first global hybrid radio platform to be commercialized around the world, supporting operations in 60 countries and currently coming to market in the new Mercedes-Benz S-Class."

16:07 EDT Beauty Health receives expected Nasdaq notification - The Beauty Health Company announced it received a notice on May 19, 2021 from the Listing Qualifications Department of The Nasdaq Stock Market indicating that as a result of the company's failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021, the company no longer complies with the continued listing requirements set forth in Nasdaq Listing Rule 5250(c)(1). The notice has no immediate impact on the listing of the company's securities, which will continue to trade on the Nasdaq Capital Market, subject to the company's compliance with other applicable continued listing requirements.

16:06 EDT ePlus has 'positive' outlook for FY22 - "Fiscal 2021 was a very successful and productive year for ePlus, as we strengthened our capabilities both organically and through acquisitions, while generating growth in adjusted gross billings, margins and earnings," the company said. "Although component shortages may delay some near-term revenue, as the market continues to evolve, we expect to see accelerated demand for collaboration, remote work solutions, security, and cloud services. We remain positive in our outlook for fiscal 2022 as ePlus continues to focus on the high growth areas that are critical to our customers' digital transformation initiatives."

16:04 EDT Ross Stores reports Q1 SSS up 13% versus 2019 - "As previously announced, financial results and guidance throughout fiscal 2021 will be compared against fiscal 2019," the company said. "We believe the significant impact from the extended closure of our operations in the spring of 2020, and the disruptions caused by COVID-19 throughout last year, make this a more relevant basis for comparison."

16:02 EDT Ross Stores authorizes new $1.5B stock repurchase program - Ross Stores said its Board of Directors authorized a new program to repurchase up to $1.5B of its common stock through fiscal 2022, with plans to buy back $650M this year and $850M in 2022. CEO Barbara Rentler noted, "The reinstatement of our share repurchase program reflects the current strength of our balance sheet, confidence in the Company's ability to generate excess cash after funding our growth and other capital needs of the business, and our long-standing commitment to enhancing stockholder value and returns."

15:30 EDT Casella Waste, Rudarpa break ground on RNG processing facility - Casella Waste Systems in partnership with Rudarpa, Inc. officially broke ground on a Renewable Natural Gas processing facility on May 19 at its North Country Environmental Services disposal facility in Bethlehem, N.H. Project partners and local officials took part in the ceremony, celebrating the official start of the project that is the first of its kind in New Hampshire. "We're thrilled to see this vision begin to take shape in Bethlehem," said Casella Chairman and CEO John W. Casella. "We're grateful to our partners who helped to develop the infrastructure that will lead to opportunity and environmental benefits for the entire state of New Hampshire and look forward to bringing the additional economic benefits to Bethlehem for years to come." The construction phase of the project is estimated to take 13 months and is expected to create up to 30 full time jobs. Once operational, up to 12 full and part time jobs are expected to be created to allow the facility to produce at capacity.

14:47 EDT FTC to proceed with administrative trial regarding charges about Illumina deal - The Federal Trade Commission announced it has authorized staff to dismiss its federal court complaint for Preliminary Injunction and Temporary Restraining Order in the case regarding Illumina's $7.1B proposed acquisition of GRAIL. Acting Bureau of Competition Director Maribeth Petrizzi issued this statement on the Commission's action: "The FTC sought preliminary relief in federal court to prevent Illumina and GRAIL from merging while the case is being decided on the merits in administrative court. At the time, a district court order was necessary to prevent the parties from consummating their merger. The administrative trial is scheduled to begin on August 24, 2021. Now that the European Commission is investigating, Illumina and GRAIL cannot implement the transaction without obtaining clearance from the European Commission." The FTC confirmed that it plans to proceed with administrative trial regarding allegations that the vertical merger would harm competition in the U.S. market for multi-cancer early detection tests. Reference Link

14:15 EDT Legend Biotech reports EMA has accepted MAA for cilta-cel in treatment of RRMM - Legend Biotech (LEGN) announces that the European Medicines Agency has accepted the Marketing Authorisation Application, or MAA, seeking approval of ciltacabtagene autoleucel, or "cilta-cel," for the treatment of patients with relapsed and/or refractory multiple myeloma, or RRMM. "The acceptance of the MAA confirms that the application is valid and marks the commencement of the EMA's assessment process. Pursuant to Legend Biotech's collaboration agreement with Janssen Biotech, Inc., Legend Biotech will receive a milestone payment of $15M relating to the EMA's acceptance of the MAA," the company stated. Janssen Biotech is a Johnson & Johnson (JNJ) company.

14:09 EDT Sysco announces $5B share repurchase authorization - Sysco announced a share repurchase authorization of $5B, to be available until fully utilized. "Today represents a pivotal moment, as we introduce our Recipe For Growth and our new purpose platform. We are creating new capabilities for Sysco that will enable us to better serve our customers, win share and increase customer loyalty. Our strategy will deliver compelling financial results and will establish a growth trajectory for the company that is fueled by our purpose," said Kevin Hourican, Sysco CEO "Only Sysco has the leadership and financial strength to deliver upon all five elements of our Recipe For Growth, further differentiating Sysco and creating a sustainable competitive advantage."

14:04 EDT Sysco board increases quarterly dividend 2c to 47c per share - The company announced that its Board of Directors acted to increase its quarterly dividend through a 2c per share increase, to 47c per share, representing Sysco's 52nd consecutive annual dividend increase. The increase will be paid as part of Sysco's regular quarterly cash dividend, payable on July 23, to common stockholders of record at the close of business on July 2.

14:01 EDT Snap announces new augmented reality tools, partnership with Farfetch - Snap announced new augmented reality tools and camera experiences for Snapchatters, creators, and businesses. "Alongside its partners, Snap is building a camera that transforms how its community interacts with the world around them through access to contextual information and richer augmented reality experiences. More than 5 billion Snaps are created every day on average, making the Snapchat camera one of the most used in the world. Snapchat opens to the camera, so it's at the center of how the global Snapchat community communicates with friends, expresses themselves, and learns about the world," the company stated. Snap added: "Snap is introducing new AR try-on experiences with fashion partners, bringing Snapchatters together with the businesses they care about through the Snapchat camera. FARFETCH provides an immersive shopping experience using 3D Body Mesh and voice-enabled controls, letting Snapchatters now say what items they're looking to browse and try on in AR. Prada is tapping into new gesture recognition capabilities that let shoppers signal to the camera when they want to try on another item."

13:59 EDT Elon Musk says has not, and won't, sell any dogecoin - Tesla CEO Elon Musk via Twitter, "Yeah, I haven't & won't sell any Doge."

13:40 EDT Poshmark jumps 8.3% to $38.22 after announcing deal with Snap

13:38 EDT Poshmark, Snap partner to bring social shopping to Snapchat with Poshmark Mini - Poshmark (POSH) announced a partnership with Snap (SNAP) to launch Poshmark Mini: a bite-sized social shopping experience of Poshmark that lives inside of Snapchat. Launching in the coming weeks, the Poshmark Mini empowers Poshmark's and Snap's social-driven communities to connect with each other and explore curated products. "Community is at the heart of everything we do, and we're focused on building the world's largest and most accessible social shopping community where everyone is welcome and anyone can thrive," said Steven Tristan Young, Chief Marketing Officer of Poshmark. "We're delighted to bring our simple, social and sustainable shopping experience to Snap, a brand that also prioritizes and fosters community. This partnership is a natural extension of our founding mission to put people at the heart of commerce and allows us to create more engaging, dynamic, and personalized shopping experiences everywhere consumers are."

13:27 EDT Google plans 'first ever physical retail store' in New York's Chelsea - In an earlier posting to Google's The Keyword blog, Jason Rosenthal VP, Direct Channels & Membership, said, in part: "Today, we're announcing our plans to open Google's first ever physical retail store, in one of the greatest cities in the world: New York. The new Google Store in Chelsea will be a space where customers can experience our hardware and services in a helpful way. We'll be opening our doors to the public in summer 2021. At the Google Store, customers will be able to browse and buy an extensive selection of products made by Google, ranging from Pixel phones to Nest products, Fitbit devices to Pixelbooks and more. Or they can shop online at GoogleStore.com and pick up their orders in store. Throughout the store, visitors will be able to experience how our products and services work together in a variety of immersive ways, which we're excited to share more about when the doors open. We'll have experts on hand to help visitors get the most out of their device, such as troubleshooting an issue, fixing a cracked Pixel screen or helping with installations. It doesn't matter whether you're a longtime Pixel user, are curious about our Nest displays or want to participate in one of the how-to workshops we'll offer throughout the year - our team will be able to provide you with help that's specific and personalized to your needs. " Reference Link

12:45 EDT BMW sees positive EUR 1B impact in Q2 from legal revaluation - Based on the progress of the proceedings, BMW said it expects, compared with the statement of objections of April 5, 2019, that the EU Commission will "significantly reduce" its allegations against the company in terms of content and duration. The subject matter of the proceedings is whether German automobile manufacturers cooperated in technical working groups to restrict competition in the development and rollout of emission-reduction technologies. The legal conformity of diesel vehicles is not subject of the proceedings. The BMW noted that it has not and has not been accused of unlawful manipulation of emission control systems. In April 2019, BMW recognized a provision of around EUR 1.4B. Based on the new information, BMW continues to consider it more likely than not that the EU Commission will issue a fine to BMW. "However, the significant limitation in the scope of the allegations has led to a revaluation of the provision," the company said. This revaluation will result in a positive effect on earnings of around EUR 1B in Q2. This effect on earnings is not included in the current guidance for 2021 and will lead to an increase in the EBIT margin for the Automotive segment of around one percentage point. BMW continues to expect a "significant increase" in earnings before taxes in the current financial year. "If the allegations are significantly reduced as expected, BMW AG would refrain from taking legal action against the issuance of any fine," it added.

12:30 EDT Sysco to acquire Greco and Sons, terms not disclosed - Sysco Corporation announced it has entered into an agreement to acquire Greco and Sons, an independent Italian specialty distributor in the United States from Arbor Investments and the Greco family. Greco and Sons operates 10 distribution centers servicing 22 geographies nationwide, with approximately $800M in annual revenue. "We are excited to welcome Eddie Greco and the rest of the Greco and Sons family to Sysco. The addition of this great company to Sysco's portfolio of specialty companies will enable us to better serve Italian-focused customers by establishing a new Cuisine-Focused Selling platform. Greco has perfected a go-to-market approach to serve the Italian segment, and we are committed to maintaining that excellence and expanding the capability to new geographies, over time," said Kevin Hourican, Sysco's president and chief executive officer. "The Greco team will bring significant experience and considerable expertise to this high growth sector, along with a track record of exceptional customer service and an extensive selection of exclusive premium products. Our combined value proposition will help both our companies achieve greater growth through a highly differentiated and tailored customer experience." The acquisition is subject to regulatory approval and other customary closing conditions.

12:14 EDT Twitter starts rolling out new verification application process - Twitter said that, starting today, it will begin rolling out its new verification application process and reviewing public applications for verification on Twitter. "Over the past several months, we've been working to bring clarity to the verification eligibility criteria and launched a new policy shaped by public feedback," the company said. "We also started enforcing that policy by automatically removing the verified badge from accounts that no longer meet the updated criteria for verification, such as those that are inactive or incomplete. We're grateful for all who participated in our public feedback period and shared ideas for how we can improve verification on Twitter." To qualify for verification, accounts must fit the criteria of one of six categories, namely government; companies, brands, and organizations; news organizations and journalists; entertainment; sports and gaming; and activists, organizers, and other "influential individuals." Reference Link

12:00 EDT Abercrombie & Fitch falls -8.4% - Abercrombie & Fitch is down -8.4%, or -$3.41 to $37.13.

12:00 EDT Saint-Gobain acquires Chryso for enterprise value of EUR 1.02B - Saint-Gobain today announces having entered into an agreement to acquire Chryso, a provider of construction chemicals, from funds advised by Cinven. The company employs about 1,300 employees and generated over the last twelve months revenues of approximately EUR 400M and an EBITDA of EUR 85M. "The acquisition of Chryso perfectly fits within Saint-Gobain's strategic vision of worldwide leadership for sustainable construction. It will further expand the Group's presence in the growing construction chemicals market with combined sales of more than EUR 3 billion across 66 countries," Saint-Gobain said in a statement. The enterprise value of EUR 1.02B represents a multiple of 12.0 times Chryso's last twelve months EBITDA. Saint-Gobain will fully finance the acquisition using the proceeds from divestments.

12:00 EDT Lightspeed POS rises 13.7% - Lightspeed POS is up 13.7%, or $7.86 to $65.30.

12:00 EDT Nam Tai Property rises 14.8% - Nam Tai Property is up 14.8%, or $2.98 to $23.06.

11:31 EDT Cato Corp. trading halted, news pending

11:05 EDT Robinhood launches product to buy shares at IPO price before public - Robinhood said on its website, "Today, we're starting to roll out IPO Access, a new product that will give you the opportunity to buy shares of companies at their IPO price, before trading on public exchanges. With IPO Access, you can now participate in upcoming IPOs with no account minimums. Most IPO shares typically go to institutions or wealthier investors. With IPO Access, everyday investors at Robinhood will have the chance to get in at the IPO price...Discover upcoming IPOs from a list of participating companies that plan to distribute shares to Robinhood...Request to buy shares of companies at their initial listing price range. When the final price is set, you'll be able to review, edit, or cancel your request, before shares are allocated to Robinhood customers...Watch and wait-IPO shares can be very limited, but all Robinhood customers get an equal shot at shares regardless of order size or account value." Reference Link

10:11 EDT Bionano Genomics granted patent for genomic coverage measurements - The United States Patent and Trademark Office posted on its website a patent for Bionano Genomics relating to the reduction of bias in genomic coverage measurements. Shares of Bionano are up 20c to $5.80 in morning trading. Reference Link

10:00 EDT Triumph Group falls -8.0% - Triumph Group is down -8.0%, or -$1.32 to $15.13.

10:00 EDT Kohl's falls -10.6% - Kohl's is down -10.6%, or -$6.36 to $53.89.

10:00 EDT Lightspeed POS rises 14.3% - Lightspeed POS is up 14.3%, or $8.23 to $65.67.

09:50 EDT EZGO Technologies to acquire land, factory building for $10.2M - EZGO Technologies announced that the Company has agreed to acquire land and factory buildings owned by Tianjin Jiahao Bicycle Co. for a total purchase price of approximately $10.2M. The transaction is expected to close by June 15, 2021. With the completion of this transaction, Jiangsu Baozhe Electric Technology, the domestic operation company of EZGO, will have more than 35,000 square meters of factory land, including two factory buildings and an administration building, and a construction area of approximately 11,000 square meters. EZGO will also have the flexibility to construct an additional 40,000 square meters of production factory buildings on this land, located in the Beijing-Tianjin Science and Technology Valley in the Wuqing District of Tianjin, which is a part of China's Bicycle Kingdom Industrial Zone. Home to several reputable technology enterprises, this model industrial park in Tianjin is one of the most important centers of the parts supply chain for China's e-bicycle industry. The Tianjin Jiahao property is conveniently and strategically located less than 1/2 km away from the Beijing-Tianjin Expressway entrance. The estimated production capacity of the existing factory buildings purchased in this transaction is 100,000 units of two-wheeled e-bicycles. The estimated production capacity of the factory building expected to be built on the remaining land being purchased is anticipated to be approximately 500,000 units of two-wheeled e-bicycles. EZGO's current production capacity at its previously leased factory in Nancai Town of Tianjin was nearly 300,000 e-bicycles, with actual capacity of 150,000 e-bicycles due to limited turnover space. This purchase will enable EZGO to significantly ramp production of its e-bicycles following the Company's successful application for the national first-class electric motorcycle qualification.

09:47 EDT KE Holdings falls -8.2% - KE Holdings is down -8.2%, or -$4.11 to $46.15.

09:47 EDT Lightspeed POS rises 8.0% - Lightspeed POS is up 8.0%, or $4.57 to $62.01.

09:47 EDT Virgin Galactic rises 22.0% - Virgin Galactic is up 22.0%, or $3.80 to $21.07.

09:42 EDT BJ's Wholesale doesn't see Q1's merchandise margin improvement recurring

09:39 EDT Alkermes appoints Emily Peterson Alva to board with support from Elliott - Alkermes earlier today announced the appointment of a new independent director, Emily Peterson Alva, to the company's board. A former Lazard M&A Partner with more than 15 years of investment banking experience, Alva "brings significant experience navigating complex strategic, transactional and governance matters for public companies across many sectors including specific expertise in healthcare and pharmaceuticals," Alkermes said in a statement. "Elliott strongly supports Emily's appointment to the Alkermes Board and its newly formed Financial Operating Committee," said an Elliott Advisors spokesperson. "Emily brings significant financial and strategic expertise to the Board. This is another welcome step by Alkermes to drive value creation for shareholders as the company implements its Value Enhancement Plan and builds on recent operational progress."

09:32 EDT Ralph Lauren sees double digit growth in each region in FY22

09:29 EDT Color Star Technology signs MOU with Movie Planet, Youa Group - Color Star Technology announced the signing of a Memorandum of Understanding on April 23 through its wholly-owned subsidiary, Color China Entertainment Co., Ltd., Movie Planet, and a South Korea-based company, Youa Group. Pursuant to the MOU and subject to definitive agreements, the three parties will aim to jointly develop a NFT application for the Hollywood Film Festival and International Film Festival databases.

09:25 EDT Telus investing $8M to accelerate deployment of high-speed, 5G networks - TELUS announces a private investment of $8M in the Cote-Nord region in 2021 for the deployment of 5G technology to ten communities, as well as the expansion of its PureFibre network to families and businesses in Havre- Saint Pierre. Since last spring, they can already enjoy great symmetrical download speeds with a direct link to fiber optics, the fastest and most reliable Internet technology in the world. With additional financial support of $ 3 million from the governments of Quebec and Canada, TELUS will continue to deploy its high-speed and wireless networks in 2022 in the communities of Longue-Pointe-de-Mingan, Mingan and Port-Menier, which will help bridge digital divides and stimulate innovation in businesses, local organizations and the health and education sectors.

09:18 EDT Huntington Ingalls debuts Proteus unmanned surface vessel - Huntington Ingalls Industries announced the debut of the Proteus unmanned surface vessel (USV) for testing and development of autonomy capabilities. The 27-foot Proteus USV was outfitted with Sea Machines Robotics' SM300 autonomy system and completed a successful demonstration on Friday, May 14 off the coast of Panama City, Florida.

09:16 EDT Verizon tests 5G Ultra Wideband to enhance hockey fan experience - Verizon is testing how 5G Ultra Wideband can bring hockey fans in the stands closer to the action on the ice by giving them real-time player stats when they point their 5G phone at the action in the rink. The company has been using 5G and mobile edge compute to power select trials for in-venue, interactive applications with the National Hockey League, such as real-time access to video highlights and player tracking data using augmented reality. As part of Verizon's official 5G partnership with the NHL, Verizon is currently working with arena operators to install Verizon 5G Ultra Wideband in select U.S. NHL arenas to bring the power of 5G to center ice.

09:14 EDT ModivCare partners with Michigan Department of Community Health, FEMA - ModivCare is providing much-needed transportation services to Michigan residents in Wayne, Oakland, and Macomb counties wishing to receive the COVID-19 vaccine who face transportation insecurity and are unable to access the mass vaccination site. The door-to-door service is being provided by one of ModivCare's local transportation partners, M RUN LLC, based out of Warren, MI and serving the metro Detroit area. ModivCare began offering rides the same day Ford Field opened its doors as the state's first federally operated mass vaccination clinic on March 23.

09:13 EDT Ralph Lauren 'optimistic' on more favorable operating environment ahead

09:12 EDT Uniti Group CFO Mark Wallace to take leave of absence - Uniti Group announced that its CFO Mark Wallace, is taking a leave of absence due to health reasons, effective immediately. The Company's Board of Directors has appointed Paul Bullington as interim CFO and Principal Financial Officer. Mr. Bullington currently serves as Senior Vice President of Strategic Operations at Uniti Fiber.

09:11 EDT ANVISA authorizes Sorrento Phase 2 trial of COVI-MSC in COVID-19 patients - Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency to proceed with a Phase 2 Pivotal clinical trial of COVI-MSC, an injectable infusion of mesenchymal stem cells, for the treatment of hospitalized COVID-19 patients suffering from ARDS. The Brazil study is a Phase 2 Pivotal, multi-center, randomized, controlled study to evaluate the safety and efficacy of three infusions of COVI-MSC, administered every other day, to hospitalized patients experiencing moderate or severe COVID-19 with ARDS. The study is expected to enroll 100 patients in three months from the date of first enrollment. Sorrento expects this projected pace of enrollment due to the extensive COVID-19 disease burden in Brazil, Sorrento's partnership with a leading local clinical research organization, and existing relationships with high quality medical centers throughout the country. The current partnership with Synova Health leverages high quality clinical trial sites in addition to a dozen centers already enrolling COVID-19 patients for another Sorrento Phase 2 clinical trial. Additional studies are also being discussed for early clearance in parallel or immediately following this study. Priority access to multiple trials is being given to Brazilian patients following the rapid and openly collaborative interactions Sorrento has been able to establish with ANVISA regulators.

09:10 EDT Esco Technologies to acquire Altanova Group, terms not disclosed - ESCO Technologies announced that it has entered into an agreement to acquire I.S.A Altanova Group S.R.L. Altanova offers a wide range of diagnostic products, monitoring systems, and services for electrical assets related to power generation, transmission and distribution networks, renewable energy and storage, and process industries, worldwide. The transaction is subject to Italian regulatory approval and is expected to close in the next 45 days. Altanova has its roots in three strong, long-experienced companies: ISA, TECHIMP and IntelliSAW which collectively provide synergies to the benefit of its customers in terms of giving access to new solutions and emerging technologies. The group leverages a worldwide geographical presence through its brands, thanks to a number of offices and subsidiaries around the world. Headquartered in Taino, Italy, Altanova provides products and services in more than 100 countries, and its strong market share in Europe and Asia creates a significant international platform for ESCO's Utility Solutions Group and fills important product gaps and geographies currently not served by USG's existing products and solutions. This acquisition positions ESCO to capture additional growth on a global scale as power infrastructure around the world continues to be developed and upgraded. Altanova, which will become part of the USG operating segment, had 2020 calendar year sales of approximately $30M with operating margins slightly above the USG segment in total. Mr. Gino Amadi, founder and a shareholder of Altanova, currently serves as Chief Executive Officer of Altanova and has agreed to remain with the company subsequent to closing.

09:09 EDT Cigna, Oscar Health expand small business health plans in Arizona - Cigna (CI) and Oscar Health (OSCR) announced that Cigna Administered by Oscar small group health insurance will be available to Arizona employers across Apache, Cochise, Coconino, Gila, Graham, Greenlee, La Paz, Maricopa, Mohave, Navajo, Pima, Pinal, Santa Cruz, Yavapai, and Yuma counties starting July 1, 2021."This pandemic has forced small business owners in Arizona to make many sacrifices, especially when it comes to their health care choices," said Bruce Grimm, Cigna's senior vice president of segments. "As more workplaces reopen, maintaining a safe workplace is vital to helping employees have peace of mind. Through our partnership with Oscar, we are providing more choices for affordable, predictable and simple health coverage to small businesses at a time when they need it most." Small businesses throughout Arizona continue to struggle from the impact brought on by the COVID-19 pandemic. According to the Census Bureau's Small Business Pulse Survey, 30.2 percent of small businesses in Arizona reported a decline in revenue during the first week of October 2020. A survey conducted by Cigna Administered by Oscar found that 88 percent of small businesses plan to better prioritize their employees' health moving forward, and 66 percent say that health insurance is more important to calculate in their budgets than before the outbreak of COVID-19.

09:06 EDT Nuvei granted approval to process sports betting payments in Michigan - Nuvei Corporation announced that its wholly owned subsidiary has been granted approval by the Michigan Gaming Control Board to provide its services to licensed and regulated online sports betting and iGaming operators within the state. Nuvei is currently permitted to provide its services to licensed and regulated online sports betting operators in 10 states.

09:06 EDT IBM selected by Pitney Bowes for global hybrid cloud transformation - IBM (IBM) and Pitney Bowes (PBI) signed an agreement under which IBM will deliver IT automation, machine learning and managed infrastructure services designed to help Pitney Bowes embrace hybrid cloud computing to support its global business plan and goals. IBM is delivering IT automation, machine learning and managed infrastructure services to help Pitney Bowes transform and embrace hybrid cloud computing. Under the agreement, IBM will manage core infrastructure domains including servers, storage systems, end-user computing, and networking for Pitney Bowes, while helping to keep critical business systems running efficiently. IBM and Pitney Bowes signed their global hybrid cloud infrastructure transformation agreement in Q1.

09:04 EDT Ford, SK Innovation announce MoU to create BlueOvalSK battery cell JV - Ford and SK Innovation announced they have signed an MoU to create a joint venture BlueOvalSK to produce approximately 60 GWh annually in traction battery cells and array modules, starting mid-decade, with potential to expand. The creation of the JV is subject to definitive agreements, regulatory approvals and other conditions. Next-gen cells and arrays will be used to power several future Ford battery electric vehicles. Ford's global BEV plan calls for at least 240 gigawatt hours, or GWh, of battery cell capacity by 2030 - roughly 10 plants' worth of capacity. Approximately 140 GWh will be required in North America, with the balance dedicated to other key regions, including Europe and China.

09:04 EDT CVS Health announces new Clinical Trial Services business - CVS Health announced its new Clinical Trial Services business that brings together innovation and experience to help solve challenges, driving greater access to clinical trials across the communities it serves and creating a more efficient, convenient experience to improve participant retention and research effectiveness. CVS Health Clinical Trial Services is working with key stakeholders in the biopharmaceutical industry and across the clinical trial ecosystem to design and deliver innovative approaches to research and real-world evidence generation. The new business will initially focus on scaling three core capabilities: Precision patient recruitment: Leveraging analytics, national reach, and local community connections to engage individuals by helping them learn about clinical trial opportunities that may be appropriate for them. Clinical trial delivery: Innovative, decentralized options for the delivery of Phase III/IV clinical trials and real-world evidence studies at CVS locations, at home or virtually. Real-world evidence generation and studies: Retrospective and prospective studies that measure the impact of novel devices and therapeutics in real-world settings.

09:03 EDT Onconova announces one-for-fifteen reverse stock split - Onconova Therapeutics announced a one-for-fifteen reverse stock split of its common stock, effective May 20, 2021. Beginning at the open of trading on May 21, 2021, Onconova's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis. At Onconova's 2021 reconvened annual meeting of stockholders on April 30, 2021, Onconova stockholders authorized the Company's Board of Directors to amend the Tenth Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio in the range of one-for-five to one-for-fifteen. Onconova's Board of Directors subsequently approved a reverse stock split ratio of one-for-fifteen, and the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation to effect the reverse stock split, which became effective upon the filing of the Certificate of Amendment with the Secretary of State of the State of Delaware on May 20, 2021. Upon effectiveness of the reverse stock split, each fifteen shares of Onconova's common stock, par value of $0.01 per share, issued and outstanding immediately prior to the effective time automatically were reclassified, combined, converted and changed into one fully paid and non-assessable share of common stock, par value of $0.01 per share. In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding options, warrants, and convertible preferred stock entitling the holders to purchase shares of our common stock. In particular, at the effective time of the reverse stock split, the Company adjusted its outstanding tradable warrants currently trading on the Nasdaq Capital Market under the symbol "ONTXW" in accordance with the terms of such tradable warrants to reflect the reverse stock split. As a result of these adjustments), each tradable warrant now entitles its holder to purchase one- two hundred and twenty-fifth of a share of Onconova's common stock at an exercise price of $1,107.00 per share of common stock. No fractional shares will be issued as a result of the reverse stock split. Instead, Onconova's stockholders who otherwise would have been entitled to a fraction of a share, will receive a full share of common stock. If a holder of the tradable warrant would be entitled to receive a fraction of a share upon the exercise of the warrant, such fractional share will be rounded down to the nearest whole share. Fractional shares resulting from exercise of other common stock warrants and conversion of outstanding convertible preferred stock will be rounded in accordance with the terms of such securities. The reverse stock split will decrease the number of common shares issued and outstanding from approximately 236.714 million shares to approximately 15.781 million shares.

09:01 EDT PrairieSky Royalty receives TSX approval for renewed Normal Course Issuer Bid - PrairieSky Royalty is pleased to announce that the Toronto Stock Exchange has accepted the notice of PrairieSky's intention to commence a normal course issuer bid. PrairieSky previously purchased an aggregate of 9,934,091 common shares at a weighted average price per share of $9.58 under a normal course issuer bid that ran between May 19, 2020 and May 18, 2021. On April 19, 2021, PrairieSky announced its intention to seek TSX approval to renew its NCIB for an additional one-year period. The NCIB allows the Company to purchase up to 15,135,000 common shares which represents 6.8% of the common shares outstanding of 222,442,900 as of May 12, 2021, and 10% of the public float of 151,354,864 common shares which is defined as the common shares outstanding after excluding common shares beneficially owned by directors and executive officers of PrairieSky and persons who beneficially own or exercise control or direction over more than 10% of the issued and outstanding common shares of PrairieSky. The NCIB will commence on May 25, 2021 and will expire no later than May 24, 2022. PrairieSky has entered into an automatic purchase plan with its broker, Stifel Nicolaus Canada Inc., in order to facilitate purchases of its common shares. The automatic purchase plan allows for purchases by the Company of its common shares at any time, including, without limitation, when the Company would ordinarily not be permitted to make purchases due to regulatory restriction or self-imposed blackout periods. Purchases will be made by PrairieSky's broker based upon the parameters prescribed by the TSX and the terms of the parties' written agreement. PrairieSky currently intends to purchase up to a maximum of 15,135,000 common shares to effect NCIB purchases over the next 12 months. However, the Company's board of directors may consider, from time to time, applying to the TSX to increase the amount of NCIB purchases. Decisions regarding increases to the NCIB will be based on market conditions, share price, best use of available cash, and other factors including other options to expand our portfolio of royalty assets.

08:57 EDT Amerant Mortgage acquires First Mortgage Company, terms not disclosed - Amerant Mortgage, a joint venture between Amerant Bank and a team of highly specialized professionals in the residential mortgage arena, announced that it had acquired Boise, Idaho-based First Mortgage Company. With the acquisition, First Mortgage was re-branded as Amerant Mortgage and will retain all its existing employees. The office will be Amerant's first outside of Florida. Founded in 1987, First Mortgage processes, underwrites, closes, and funds mortgage loans, and has earned a reputation over the decades for their capabilities in meeting the diverse financial needs of their clients.

08:55 EDT Ecolab launches Cockroach Multi-Station device for foodservice operations - Ecolab has launched the Cockroach Multi-Station, an innovative, discreet and durable device designed to detect the arrival of cockroaches early and provide ongoing defense to help foodservice providers ensure clean and safe operations.

08:53 EDT Troika Media, Stampede Ventures support Dole's partnership with Datuna - Troika Media Group announced that in collaboration with Stampede Ventures, an LA-based content creation company, the Company's New York-based Mission group was engaged to launch a new non-fungible token series based on a partnership between the Dole Sunshine Company and the "Hungry Artist" David Datuna. The five-piece series includes four fruit-inspired NFTs and a final fifth piece, Sunshine for All.

08:51 EDT CPI Aerostructures signs $17.2M long-term agreement with Sikorsky - CPI Aerostructures (CVU) announced that it has entered into a new Long-Term Agreement with Sikorsky Aircraft, a Lockheed Martin Company (LMT), to overhaul and repair outboard stabilator assemblies in support of the Sikorsky MH-60 SEAHAWK Performance-Based Logistics Program. The Company estimates this new LTA is valued at $17.2 million over a term that ends in 2027 and includes a single option for an additional two years.

08:50 EDT Predictive Oncology's TumorGenesis partners with Cellevate - Predictive Oncology announced that its wholly owned subsidiary, TumorGenesis, has partnered a deal with the Swedish firm Cellevate AB. The companies are combining TumorGenesis' medias with Cellevate's high engineered matrix materials. This partnering opens new territories for both companies.

08:47 EDT WisdomTree announces launch of Efficient Core family of ETFs - WisdomTree announced the launch of the Efficient Core family of ETFs, which includes the International Efficient Core Fund and the Emerging Markets Efficient Core Fund on the NYSE with expense ratios of .26% and .32% respectively. In addition, effective today, the WisdomTree 90/60 U.S. Balanced Fund is renamed as the WisdomTree U.S. Efficient Core Fund. The WisdomTree Efficient Core suite seeks to leverage the benefits of overlays providing fixed income exposure in seeking to provide capital efficiency of U.S., international, and emerging equity markets.

08:45 EDT Marathon Digital appoints Georges Atoun, Jay Leupp to board of directors - Marathon Digital Holdings has appointed Georges Antoun and Jay Leupp to its board of directors, effective immediately, as Peter Benz transitions to become the company's vice president of corporate development and Michael Berg steps down from his position of director to pursue other projects. As a result, Marathon's board of directors now consists of five directors, including three independent directors and two inside directors. Antoun currently serves as the president of First Solar where he was chief operating officer before being appointed to president, U.S. in July 2015. Jay Leupp is the managing partner of Terra Firma Asset Management. Benz has served on Marathon's board of directors since November 2020 and is transitioning from a member of the board of directs to an executive officer. In his new position as vice president of corporate development, Mr. Benz will be responsible for providing strategic direction and acting as a thought leader whose primary responsibilities include developing and executing innovative strategies to fortify and expand Marathon Digital Holdings' leadership position in the bitcoin mining industry.

08:40 EDT CPS Technologies receives additional HybridTech Armor Panels order - CPS Technologies announced the receipt of an additional purchase order for HybridTech Armor Panels to be installed as part of an integrated ballistic protection system on U.S. Navy Nimitz-class aircraft carriers from Kinetic Protection, the Navy's prime contractor. The HybridTech Armor panels are an essential component that protects sailors manning crew-served weapons stations aboard the Naval fleet. The value of this second purchase order for four additional ship sets is $5.8M.

08:39 EDT Gold Standard Ventures announces 2021 exploration, development program - Gold Standard Ventures announced plans for the 2021 exploration and development program on its vast land package in Nevada's Carlin Trend. The program includes approximately 7,880 meters of reverse-circulation and core drilling over 46 holes. Drilling is anticipated to start in May 2021. Exploration Focus Areas: Pinion SB Zone: 7 RC drill holes to further develop oxide mineralization at the SB Zone target. Previously released intercepts at SB Zone include: PR20-26, PR20-30, PC20-22, and historical hole PIN14-38; the deposit remain open to the south and east in this target zone. Dark Star: 30 RC and core drill holes to define the limits of near-surface oxide mineralization at Dark Star Main, convert Inferred resources within the mine plan boundary to Measured or Indicated resources, and complete metallurgical core holes for test work in support of future mining and processing. LT: 5 RC drill holes will continue to test for gold mineralization along the LT Fault, to the north of LT20-01 and LT20-08 and structural and stratigraphic targets centered around surface channel sampling conducted in 2020. Three-meter surface channel sampling highlighted 57m of 0.61 g Au/t centered around LT20-01 and the LT-Tesla Fault intersection. Additionally, surface sampling to the south identified 18m of 4.84 g Au/t along the Lotus-LT Fault intersection. Sampling, mapping, and drilling has identified a zone approximately 200 meters long associated with the LT Fault and structural intersections with the northeast striking Tesla and Lotus faults. The mineralization remains open to the north, south, west, and at depth. Other Exploration & Development Work: Pinion: 4 RC drill holes to advance metallurgical and hydrology test work and support mine start-up. South Dome: Exploration will focus on compiling results from the soil survey and geologic mapping completed in 2020. Work to date has identified a domal feature within Pinion stratigraphy that has elevated gold, silver, arsenic and mercury in soils. The goal is to advance the project to a drill decision by the end of year.

08:37 EDT Rain Therapeutics appoints Robert Doebele as president - Rain Therapeutics announced the appointment of Rain co-founder Robert Doebele, M.D., Ph.D. as president and chief scientific officer. As president, Dr. Doebele will play a critical role in shaping the company's corporate strategy and operations and will continue to provide his precision oncology expertise to advance Rain's clinical pipeline and lead the company's research and development efforts as CSO. Dr. Doebele co-founded Rain Therapeutics with Mr. Vellanki in April 2017 and has served as executive vice president and CSO.

08:35 EDT Morgan Stanley appoints Jonathan Pruzan as COO, Sharon Yeshaya as CFO - Morgan Stanley announced that Ted Pick and Andy Saperstein have been named co-presidents of Morgan Stanley. Both executives are long-serving employees in management positions and both head businesses with. Pick leads Morgan Stanley's institutional securities business and will now also be responsible for Morgan Stanley's international operations and become the co-head of firm strategy and execution. Saperstein leads Morgan Stanley's wealth management business and will now be responsible for all wealth management channels, including Financial Advisors, E-Trade and Morgan Stanley at Work. He will also assume responsibility for firmwide marketing globally. Dan Simkowitz, the head of investment management, will in addition be co-head of firm strategy and execution with Pick and will continue to report to James Gorman, Morgan Stanley's chairman and CEO. Jonathan Pruzan, currently Morgan Stanley's CFO, will become COO, with responsibility for technology, operations and firm resilience; Morgan Stanley's U.S. Banks, and corporate services. Sharon Yeshaya, currently the head of investor relations, will replace Pruzan as CFO, reporting to both Pruzan and Gorman. All of these appointments become effective on June 1.

08:34 EDT Anixa Biosciences requested additional data for CAR-T IND application by FDA - Anixa Biosciences announced that the FDA has provided details of the additional information it is requesting regarding its Chimeric Antigen Receptor-T cell therapy - CAR-T - being developed in partnership with Moffitt Cancer Center. The Investigational New Drug application for this study was submitted in March, and the FDA subsequently requested additional information before approving the trial. Anixa and Moffitt believe that the requested information can be assembled and provided to the FDA within approximately 30 days, after which the FDA will again respond within 30 days after the submission. The therapeutic product is comprised of engineered T-cells that target the follicle stimulating hormone receptor.

08:33 EDT Beyond Air appoints Rebecca Van Doren as head of sales - Beyond Air announced the appointments of Rebecca Van Doren as Head of Sales and Kori-Ann Taylor as Head of Marketing. Van Doren brings over 20 years of healthcare leadership and sales experience to Beyond Air, dedicating the majority of her career to envisioning and invigorating winning commercial strategies for nitric oxide, both in the US and Australia with Ikaria and Mallinckrodt Pharmaceuticals. Taylor joins Beyond Air from aptihealth, where she served as the Chief Marketing Officer, responsible for brand building, developing, and leading all marketing initiatives and launches across health plans and hospital systems.

08:28 EDT Cypress Development says equipment deliveries on track for Nevada pilot plant - Cypress Development Corp. is pleased to provide an update on its ongoing pilot plant construction in Nevada. Equipment deliveries are on track and plant assembly is expected to commence by month end at the leased facility in Amargosa Valley. The plant remains on schedule is expected to be fully operational in July 2021. The Company has entered into a services agreement with Chemionex, an Ontario based company and innovator in hydrometallurgical process development and direct lithium extraction technology to advise on the DLE section of the pilot plant. Chemionex's owner, Craig Brown, is an internationally recognized expert on aqueous-based chemical separations in the field of ion exchange, with extensive experience in electrochemistry, adsorption, filtration, membranes, evaporation and crystallization. The pilot plant is intended to confirm the extraction of lithium from the Company's Clayton Valley Lithium Project, in accordance with the recommendations outlined in the Company's Prefeasibility Study. The initial operation of the pilot plant will focus on chloride-based leaching to confirm the previously announced results The plant at the Amargosa Valley site will be configured into three primary sections: leaching, tailings handling and DLE. Offsite testing of product and stripped leach solutions will be conducted at NORAM Engineering and Construction Ltd's BC Research laboratory in Richmond Canada. The overall plant operation will be supervised by Continental Metallurgical Services LLC in conjunction with Cypress and del Sol Refining personnel. Each section in the plant will have specific objectives. The leaching section will work to optimize leach conditions and confirm lithium extraction into pregnant leach solution. The tailings handling section will utilize a counter current decantation arrangement of thickener settlers and flocculant mixing determined by Pocock Industrial with the objective of determining materials handling, moisture content and water consumption. Chemionex, under a separate purchase agreement, will provide the equipment for the DLE section of the pilot plant. Additionally, Cypress will be granted an option upon completion of the pilot plant program to license Chemionex's proprietary Lionex DLE technology for commercial use at its Clayton Valley Lithium Project. Both the purchase and option agreements are at advanced stage of preparation. The work conducted by NORAM Engineering will treat the concentrated lithium solution from the DLE portion of the pilot plant to produce lithium hydroxide and test the stripped leach solution for compatibility in recycling to the leaching portion of the plant. The Company is proceeding with the due diligence work with respect to its recently announced letter agreement for water rights with Nevada Sunrise Gold Corp. The parties are working towards completion of a purchase agreement on or before June 7, 2021. The Company also recently leased a 20-acre industrial site near Tonopah, Nevada. The location is at the site of a previous gold milling operation. Cypress is renovating the site which it intends to use for administrative purposes in conjunction with the Clayton Valley Lithium Project.

08:26 EDT W.R. Grace completes expansion of Kuantan, Malaysia plant - W. R. Grace & Co. announced completion of the expansion of its manufacturing plant in Kuantan, Malaysia. Kuantan, the capital and major seaport town of Pahang, Malaysia, has been home to Grace Specialty Chemicals Sdn Bhd since 1996. The expansion is Grace's fourth extension of the plant since its inception and a direct result of growing worldwide demand for Grace's specialty silica solutions.

08:24 EDT Gentex ships Bluetooth-enabled mirrors to Volkswagen - Gentex Corporation (GNTX) recently began shipping to Volkswagen (VWAGY) its Bluetooth-enabled automatic-dimming mirror with HomeLink integrated buttons capable of operating a wide range of radio frequency and cloud-based smart home devices. Gentex's Bluetooth-enabled HomeLink mirror will launch with VW as an optional accessory on the 2022 Volkswagen Taos. The feature will then roll out to additional vehicles.

08:19 EDT Aemetis notified of U.S. Forest Service grant for patented process - Aemetis has been notified of a grant from the U.S. Forest Service toward the commercialization of a patented process that extracts cellulosic sugars from waste orchard wood, waste forest wood, and other biomass. The sugars from waste wood could potentially be used to produce high value cellulosic ethanol at the existing 65 million gallon per year Aemetis ethanol plant, while the remaining lignin material is expected to be used in the production of negative carbon intensity, cellulosic hydrogen for use in renewable jet and diesel production at the Aemetis Carbon Zero 1 plant being built in Riverbank, CA.

08:17 EDT Seres Therapeutics announces David Arkowitz to join as EVP CFO - Seres Therapeutics announced that David Arkowitz will join as Executive Vice President, Chief Financial Officer and Head of Business Development, effective June 1. Mr. Arkowitz will report directly to Eric Shaff, President and Chief Executive Officer of Seres. "I am excited to welcome David to the Seres leadership team. He is a key addition as we continue to lead the development of a potentially new class of transformative treatments across multiple diseases," said Mr. Shaff. "His track record in leading finance functions and operations, combined with his impressive business development and commercial experience, will strongly support our growth."

08:16 EDT Entera Bio expects cash to fund operations into 2Q22 - Entera expects an operating loss of approximately $13.0 million for the year ending December 31, 2021 and believes its current cash position will be sufficient to fund its operations into the second quarter of 2022.

08:13 EDT Zealand Pharma increases share capital as result of employee warrants exercise - Zealand Pharma has increased its share capital by a nominal amount of DKK 2,000 divided into 2,000 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand Pharma's employee warrant programs. The exercise price was DKK 135.30 per share for the 2,000 new shares and the total proceeds to Zealand Pharma from the capital increase amount to DKK 270,600. The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand Pharma's general meetings. Zealand Pharma has only one class of shares. The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand Pharma will be nominal DKK 43,451,842 divided into 43,451,842 shares with a nominal value of DKK 1 each.

08:08 EDT NeuBase Therapeutics appoints Sandra Rojas-Caro as CMO - NeuBase Therapeutics (NBSE) announced the appointment of Sandra Rojas-Caro, M.D., as Chief Medical Officer, effective May 24, 2021. Dr. Rojas-Caro will oversee the preclinical and clinical development, medical, and regulatory strategy of NeuBase's pipeline to address disease at its base cause. Most recently, she was Chief Medical Officer for Gemini Therapeutics (GMTX), a company focused on redefining age-related macular degeneration and linked disorders with precision medicine.

08:05 EDT Fair Isaac appoints Ben Nelson as Chief Information Security Officer - Fair Isaac appointed Ben Nelson as Chief Information Security Officer. Prior to joining FICO, Nelson was chief information security officer at Tableau, a Salesforce company, as well as vice president of cloud security, at Oracle.

08:03 EDT BlueCity CFO Zhiyong Li resigns, Junchen Sun succeeds - BlueCity announced that Zhiyong Li resigned from his position as CFO due to personal reasons, effective May 20. Li will serve as the company's financial advisor for the next six months. Junchen Sun, the company's VP, Finance, will assume the role of acting CFO of the company effective upon Li's departure. Sun joined BlueCity in February 2017. He previously served as financial controller at MicroMedia Holdings Limited from 2015 to 2017 and senior associate at PricewaterhouseCooper Zhong Tian LLP, Tianjin branch from 2011 to 2015.

08:02 EDT ViaSat, NBA partner on NBA League Pass - The National Basketball Association and Viasat announced a groundbreaking multi-year partnership to make NBA League Pass, the league's premium live game subscription service, available to millions of airline passengers while in flight. The partnership will provide a streaming experience in the sky, enabling airline passengers to access live and on-demand NBA games and content on their personal electronic devices at no extra cost when they register for NBA League Pass in-flight. JetBlue will be one of the first airlines to offer NBA League Pass on Viasat-equipped aircraft, with additional airlines expected to be announced. Available during the 2021 NBA Playoffs, which will tip off Saturday, May 22, Viasat will enable access to the premium version of NBA League Pass - featuring every NBA game live and on-demand - to passengers onboard aircraft with Viasat In-flight connectivity. NBA League Pass will be available on any route, except for flights within the U.S., Canada and China; international flights to and from these three countries will also have access to the service.

07:46 EDT NFI Group, BYD partnership delivers 500th electric bus - NFI Group (NFYEF) announced that the BYD UK (BYDDF) and Alexander Dennis Limited electric vehicle partnership has delivered its 500th electric bus. This major milestone comes less than five years after rolling out its first battery-electric bus and will see the 500th vehicle, a zero-emission Enviro400 double deck bus, join the fleet of the partnership's original customer, Go-Ahead London. As the UK's transition to zero-emission transport continues to accelerate, the BYD ADL partnership has already taken firm orders for the next 500 electric buses for public transit operators. In a testament to the UK's leadership in zero-emission vehicle adoption, these 500 new vehicles are expected to be delivered over the next 12 months and will bring the partnership's total deliveries to over 1,000 units. .

07:42 EDT Theratechnologies announces results from two posters on Trogarzo - Theratechnologies reported on results presented in two separate posters in conjunction with ACTHIV 2021 virtual conference being held May 20-22, 2021. The first poster included findings from a survey conducted among 30 Trogarzo patients to assess real-world patient experience and acceptance of IV administration. The survey found that 100 percent of patients were either very satisfied or moderately satisfied with their experience with Trogarzo. Other highlights included: 60 percent said that their experience with Trogarzo was better than expected while 40 percent said it was about the same; 93 percent of respondents either found the IV infusion process very convenient or neutral; 93 percent said they would likely recommend Trogarzo to another patient living with HIV; 87 percent expressed very high satisfaction with the experience of receiving an infusion and seeing a healthcare professional every two weeks; and, 80 percent were of the opinion that a touchpoint every two weeks was likely to support adherence to other HIV medications. These findings are in line with conclusions drawn from a retrospective evaluation conducted by Option Care Health, a national alternate site infusion provider, and were also presented at ACTHIV 20212. The evaluation demonstrated an overall 98 percent compliance rate with Trogarzo based on 3,528 infusions administered to 130 patients between May 2018 and February 2021. Furthermore, a compliance rate with other antiretrovirals of 89 percent was observed among Trogarzo patients, supporting the patient survey findings.

07:39 EDT Field Trip Health appoints Tom Daschle as special advisor - Field Trip Health announced the appointment of former US Senate Majority Leader Tom Daschle as a Special Adviser to the Company. Daschle is one of the longest serving Senate Democratic leaders in history and one of only two to serve twice as both Majority and Minority Leader. Senator Daschle is also the Founder and CEO of the Daschle Group, a Public Policy Advisory of Baker Donelson and a legal and government affairs firm that advises clients on a broad array of economic, policy and political issues. In consideration of the services, Senator Daschle will be receiving a stipend and options consistent with grants made to the members of the board of directors of Field Trip.

07:34 EDT Lantronix announces use of Open-Q 820 uSOM in Whisper Hearing System - Lantronix announced that its Open-Q 820 microSOM was used in the development of the Whisper Hearing System. Created by San Francisco-based Whisper, the Whisper Hearing System is a learning hearing aid that gets better over time and uses artificial intelligence to process sound.

07:32 EDT Soligenix granted Japanese patent for synthetic hypericin composition - Soligenix announced that the Japan Patent Office has allowed the patent application directed to proprietary methods to produce a highly purified form of synthetic hypericin, similar to those previously allowed in the U.S. Synthetic hypericin is the active pharmaceutical ingredient in HyBryte, the company's photodynamic therapy, for which positive primary endpoint results in a pivotal Phase 3 study for the treatment of cutaneous T-cell lymphoma were recently announced. This new patent is the first allowed in Japan covering the proprietary methods developed by the company and further expands the comprehensive HyBryte patent estate. The company believes HyBryte has compelling competitive advantages over existing therapies for early stage CTCL and represents a significant commercial opportunity.

07:30 EDT ImmunoPrecise Antibodies completes four monoclonal antibody cocktail study - ImmunoPrecise Antibodies announced the completion of an efficacy-driven, preclinical study demonstrating further evidence of the in vivo efficacy of a four monoclonal antibody cocktail against non-overlapping epitopes, utilizing an optimized formulation and, for the first time, demonstrating therapeutic synergy of the cocktail components in vivo. Completed preclinical efficacy studies for its newly optimized 4-antibody cocktail, showing in vivo therapeutic efficacy and synergy for the treatment and protection against SARS-CoV-2 infection. The company believes these are the first publicly reported in vivo synergistic effects of a multi-antibody combination treatment IPA's optimized, 4-Ab cocktail shows high levels of efficacy in treating SARS-CoV-2 in the preclinical study. Updated mutant binding data demonstrates continued in vitro resistance against novel variants of concern, including the recently described Californian and New York variants. Company contracts ChemPartner Biologics for optimized, stable CHO pool generation and cell bank generation for use in cGMP manufacturing.

07:24 EDT Petco CEO says 'We entered 2021 with momentum' - "We entered 2021 with momentum, and delivered record quarterly sales in Q1 driven by our strong execution and unique model across digital and in our Pet Care Centers," said Ron Coughlin, Chairman and CEO of Petco. "We're attracting new customers and gaining market share in a growing category through our unique end to end health and wellness ecosystem. There are more pets in homes than ever and the 1.2 million net new customers we gained in the quarter is a multi-year high, that provides an annuity for years to come. The category acceleration combined with a strengthening of our customer base give us confidence to raise our full year guidance." Petco reduced total debt by 52% to $1.7B and Net Debt by 53% to $1.5B using the proceeds from the company's initial public offering, the recapitalization of a portion of debt outstanding at the time of the initial public offering and Free Cash Flow generation.

07:23 EDT Myriad Genetics appoints Melissa Gonzales as president, Women's Health Business - Myriad Genetics announced that Melissa Gonzales has been named president of its Women's Health business. Gonzales has more than 20 years of women's health experience, most recently at Medela, a global leader in breast pumps and medical solutions. In her role at Myriad Women's Health, Gonzales will be responsible for serving consumers, patients and healthcare providers with genetic tests that help women assess their risk of hereditary cancer and provide vital insights during pregnancy or when planning a family. She will report to Nicole Lambert, president of Myriad Genetic Laboratories.

07:18 EDT Plug Power names Benjamin Haycraft VP, strategy and business development, Europe - Plug Power announces Benjamin Haycraft as the Company's newest Vice President of Strategy and Business Development, Europe. Before joining Plug Power, Benjamin Haycraft advised the Company as a Santander banker, resulting in the announcement of the joint-venture projects at the start of 2021 with European leaders including the Renault Group in France and Acciona in the Iberian Peninsula.

07:17 EDT Atea Pharmaceuticals appoints Jerome Adams to board of directors - Atea Pharmaceuticals announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Directors. Dr. Adams most recently served as Surgeon General of the United States and brings a wide range of experience spanning clinical practice, clinical research, public health, and government agency leadership.

07:14 EDT Immunome announces additional $4.3M award by DOD - Immunome announced a $4.3M increase awarded by the U.S. Department of Defense's, DOD, Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense in collaboration with the Defense Health Agency , for the continued development of an antibody cocktail to combat SARS-CoV-2 and its variants. The additional capital comes less than a year after an initial DOD award of $13.3 million, bringing the total commitment to Immunome to $17.6M. The additional funding is to support expansion of the clinical study following feedback from the FDA. Immunome is continuing efforts towards an IND filing for IMM-BCP-01 in late 2Q/early 3Q 2021. IMM-BCP-01 contains three monoclonal antibodies that bind to non-overlapping regions of the spike protein with picomolar affinity. The antibodies exhibit combinatorial effects in vitro against multiple SARS-CoV-2 variants, including those exhibiting both increased transmission in the United States and resistance to current antibody therapeutics and vaccines. "We are thrilled to have secured additional funding from the Department of Defense," said Purnanand Sarma, Ph.D., President and CEO of Immunome. "We are grateful to the DOD for their continued support and we are eager to move our antibody cocktail into the clinic."

07:12 EDT Agenus presents new data on balstilimab, AGEN2373 in ASCO abstracts - Agenus announced data on the differentiated activity profile of balstilimab, an anti-PD-1 antibody, and new Phase 1 clinical data for AGEN2373, a CD137 agonist antibody, as published in abstracts for two posters to be presented at the American Society for Clinical Oncology Annual Meeting 2021 from June 4 - 8, 2021. Balstilimab has shown expanded clinical activity in a Phase 2 clinical trial for patients with recurrent or metastatic cervical cancer. Responses have been observed in both PD-L1 positive and PD-L1 negative tumors in contrast to approved anti-PD-1 antibodies which have shown almost no responses in the PD-L1 negative population. Preclinical observations using the company's proprietary platform corroborate these results, showing differentiated activity and superior tumor killing potential for balstilimab as compared to commercially available anti-PD-1 antibodies. Agenus submitted a Biologics License Application to the U.S. Food and Drug Administration on April 19 for the use of balstilimab in patients with recurrent or metastatic cervical cancer. This submission was based on data from the Phase 2 trial showing a response rate of 20% in PD-L1 positive tumors and an overall response rate of 15% with a median duration of response of 15.4 months. AGEN2373 is a conditionally active CD137 agonist antibody designed to overcome limitations seen with first-generation CD137 agonist antibodies, including the development of liver toxicity. In this first-in-human study of AGEN2373 in patients with advanced solid tumors, no dose limiting toxicities were seen at doses up to 3 mg/kg; notably, no liver toxicity has been observed. Five patients demonstrated stable disease out of 19 patients treated with AGEN2373 monotherapy, including one heavily pretreated patient with metastatic leiomyosarcoma who had progressed on prior combination checkpoint immunotherapy.

07:11 EDT Renren receives NYSE non-compliance notification from late Annual Report filing - Renren received a notice from NYSE Regulation indicating that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Annual Report for 2020 with the SEC. The company was not able to file the 2020 Form 20-F by its due date primarily due to the additional time required to prepare the company's audited financial statements for the year ended December 31, 2020. The company stated that is making all efforts to file the 2020 Form 20-F as soon as possible. If the company fails to file its annual report and any subsequent delayed filings within six months from the filing due date, the NYSE may, in its sole discretion, allow the company's securities to trade for up to an additional six months depending on specific circumstances. If the NYSE determines that an additional six-month trading period is not appropriate, suspension and delisting procedures will commence.

07:07 EDT Ball Corp. launches Aluminum Cup at major retailers in all 50 states - Ball Corporation's recyclable Ball Aluminum Cup is now available for purchase at major retailers in all 50 states across the U.S. Between May and June, the cups will be available for the first time in more than 18,000 food, drug and mass retailers, including Kroger, Target, Albertsons, CVS and others. The nationwide retail rollout follows the limited pilot that began in 2019.

07:07 EDT Sanofi to present data from Phase 1 AMEERA-1 study at ASCO - Phase 1 data from the AMEERA-1 study evaluating amcenestrant, an investigational oral selective estrogen receptor degrader, will be presented at the 2021 American Society of Clinical Oncology Annual Meeting, Sanofi announced. In a pooled analysis, amcenestrant in combination with palbociclib showed encouraging antitumor activity in postmenopausal women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, or MBC. In this preliminary analysis from the open-label AMEERA-1 study, amcenestrant was evaluated in dose escalation cohorts at 200mg and 400mg daily and in a dose expansion cohort at 200mg daily, all in combination with a standard dose of palbociclib. Eligible patients included post-menopausal women with ER+/HER2- MBC who were pre-treated with endocrine therapy in the advanced setting for at least six months or had resistance to adjuvant endocrine therapy. In the pooled population exposed with amcenestrant at 200mg daily evaluable for response, the objective response rate was 34%, with confirmed partial responses in 12/35 patients, and the clinical benefit rate was 74%, with clinical benefit in 26/35 patients at 24 weeks. Amcenestrant 200mg daily in combination with palbociclib demonstrated a favorable overall safety profile, with treatment related adverse events attributable to amcenestrant similar to those observed with monotherapy. For all grade events, amcenestrant TRAEs occurred in 72% and to palbociclib in 90% of patients, and for grade greater than or equal to3 in 15% and 46% of patients, respectively. "These early clinical data show that the combination of amcenestrant with palbociclib achieved encouraging antitumor activity. The analysis also demonstrated no clinically significant cardiac or ocular findings and an overall safety profile in line with what we saw in the monotherapy setting. It's notable to see this kind of activity in patients with ER+ metastatic breast cancer, where there is a clear need for new therapeutic options," said Sarat Chandarlapaty, M.D., Ph.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center.

07:05 EDT Cathie Wood's ARK Investment discloses 244K shares of Square bought yesterday

07:03 EDT Cathie Wood's ARK Investment discloses 69.5K shares of Tesla bought yesterday

06:58 EDT Brookfield Asset Management renews normal course issuer bid - Brookfield Asset Management has received approval from the Toronto Stock Exchange for the renewal of its normal course issuer bid to purchase up to 132,856,682 Class A Limited Voting Shares, representing 10% of the public float of Brookfield's outstanding Class A Shares. The period of the normal course issuer bid will extend from May 25, 2021 to May 24, 2022, or an earlier date should Brookfield complete its purchases. As at May 18, 2021, the number of Class A Shares issued and outstanding totalled 1,577,564,357, of which 1,328,566,827 shares represented the public float. Of the 132,829,848 Class A Shares approved for purchase under Brookfield's prior normal course issuer bid that commenced on May 25, 2020 and will expire on May 24, 2021, Brookfield purchased 1,998,400 Class A Shares through open market purchases on the TSX and 5,951,806 Class A Shares through open market purchases on the NYSE as of May 18, 2021. The weighted average price that Brookfield paid per Class A Share acquired under this bid was $38.59. Brookfield will enter into an automatic purchase plan on or about the week of June 21, 2021 in relation to the normal course issuer bid.

06:50 EDT InterCure initiates special home delivery service in collaboration with UPS - As demand for medical cannabis products during the military conflict in Israel remains solid, the company initiated a medical cannabis home delivery program in collaboration with UPS. For the first time, patients in Israel can order InterCure's high-quality branded products directly to their home with same day delivery using UPS's world renowned carrier service.

06:48 EDT BJ's Wholesale reports Q1 digitally-enabled sales growth of 31% - Digitally-enabled sales growth was 31%, reflecting a two-year stacked comp growth of 381% for the first quarter of fiscal 2021. Adjusted EBITDA increased 4.4% year-over-year to $202.4M. Net cash provided by operating activities was $249M and free cash flow was $190.9M.

06:46 EDT BJ's Wholesale not providing 'formal detailed guidance' - "Given the level of uncertainty associated with the evolution of the pandemic and consumer behavior, fiscal 2021 remains difficult to forecast," said Laura Felice, Executive Vice President, CFO, BJ's Wholesale Club. "As a result, we will continue to refrain from offering formal detailed guidance."

06:46 EDT Advanced Drainage increases dividend 22% to 11c per share - Advanced Drainage has approved a quarterly cash dividend to its shareholders in the amount of 11c per share, an increase of 2c per share, or 22%, over the prior quarter. The quarterly cash dividend of 11c per share will be paid on June 15 to shareholders of record at the close of business on June 1.

06:32 EDT Virgin Galactic confirms upcoming test flight of VSS Unity on May 22 - Virgin Galactic Holdings confirmed that the next rocket-powered test flight of SpaceShipTwo Unity will be conducted on May 22, pending weather and technical checks. This follows the completion of a maintenance review of VMS Eve, the mothership jet aircraft designed to carry SpaceShipTwo to an altitude of approximately 50,000 feet. The upcoming VSS Unity test flight will be crewed by two pilots and will carry research payloads as part of the NASA Flight Opportunities program. A key objective of the upcoming flight will be to test the remedial work that has been completed on VSS Unity to lower the EMI levels experienced on the December 12, 2020 flight when the onboard computer halted ignition of the rocket motor. The flight will also incorporate all original test objectives, including assessment of the upgraded horizontal stabilizers and flight controls during the boost phase of the flight, evaluating elements of the customer cabin, and testing the live stream capability from the spaceship to the ground. Following this May flight, and in line with normal procedures, the team will complete an extensive data review, which will inform the next steps in the test flight program.

06:28 EDT L Brands sees FY21 CapEx $400M-$450M, up $50M vs. previous forecast

06:27 EDT L Brands 'pleased' with May results to-date

06:19 EDT Genetron partners with JD.com's JD Health for full-cycle cancer management - Genetron (GTH) announced a strategic partnership with JD Health, a subsidiary of JD.com (JD). The two companies aim to create innovative solutions for full-cycle cancer management. The partnership encompasses both online and offline components, and focuses on six key areas: consumer healthcare, digitization of liver disease management, government medical associations, sharing of customer screening resources, industry and user education, and consolidation of oncology doctors and experts on a single platform. The first phase of the partnership will focus on liver and lung cancer. The company will cooperate with JD Health to cover early cancer screening, molecular profiling, therapy selection, and drug resistance monitoring, leveraging the company's HCCscreen liquid biopsy product for hepatocellular carcinoma and its NMPA-approved 8-gene lung cancer detection kit. In May and June, the company and JD Health will launch a series of HCCscreen marketing and educational activities for people at high risk of developing liver cancer.

06:12 EDT Incyte's ponatinib meets primary endpoint in Phase 2 trial for leukemia - Incyte (INCY) announced that data from the primary analysis of the Phase 2 OPTIC trial will be presented during an oral session at the 2021 American Society of Clinical Oncology Meeting June 4-8. The OPTIC trial - an ongoing, study prospectively evaluating response-based dosing regimens of ponatinib over a range of three starting doses followed by dose reduction to 15mg with the aim of optimizing efficacy and safety in patients with chronic-phase chronic myeloid leukemia who are resistant to prior tyrosine kinase inhibitor therapy - met its primary endpoint. The trial, sponsored by Takeda (TAK) and co-funded by Incyte, evaluated treatment in patients with resistant disease, with and without mutations. The results show that the optimal benefit-risk profile for ponatinib in patients with CP-CML was achieved with a starting dose of 45mg/day, and upon response, dose reduction to 15mg/day. The results also suggest a clinically-manageable safety profile for ponatinib. The 30mg/day and 15mg/day starting dose cohorts also demonstrated benefit. Rates of arterial occlusive events observed at the time of primary analysis suggest a clinically manageable safety profile. The most common treatment-emergent adverse events Grade 3 or greater were thrombocytopenia - 27% -, neutropenia - 17% - and anemia - 7% -. Incyte has an exclusive license from Takeda Pharmaceuticals to commercialize ponatinib in the EU and 29 other countries. Iclusig is marketed in the U.S. by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical.

06:04 EDT Triumph Group reports Q4 backlog of $1.9B - The company said, "Backlog, which represents the next 24 months of actual purchase orders with firm delivery dates or contract requirements, was $1.9 billion, down as expected compared to the prior year period and on a sequential basis due to divestitures, sunsetting programs and recent production rate reductions, but partially offset by military program increases in Systems & Support. For the fourth quarter of fiscal year 2021, cash flow provided by operations was $22.8 million, reflecting improved working capital and operating margins and which included liquidation of approximately $10.0 million in prior period advances against current period deliveries."

06:03 EDT Pfizer and BioNTech to supply Turkey with 60 million doses of COVID-19 vaccine - Pfizer (PFE) and BioNTech (BNTX) announced that the BioNTech Europe GmbH has entered into an agreement with Turkey's Ministry of Health to supply 60 million additional doses of the companies' COVID-19 vaccine, with an option for an additional 30 million doses. On December 25, 2020, the two companies reported an initial agreement to provide 30 million doses of the Pfizer-BioNTech vaccine to Turkey. This second supply agreement brings the total number of doses to be supplied to Turkey to up to 120 million, all of which will be delivered in 2021. The vaccine, which is based on BioNTech's proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the U.S. - jointly with Pfizer -, United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.

05:36 EDT S&P Global announces IEA to use its LNG service - S&P Global Platts announced that the International Energy Agency, or IEA, will use its Liquified Natural Gas, or LNG, service that provides LNG prices as well as data on LNG shipping and LNG plant outages.

05:32 EDT Sorrento Therapeutics announces first patient treated in Enbrel study - Sorrento Therapeutics announced that the first patient has been treated in a Phase 1b proof-of-concept, open-label study to assess the safety and pilot efficacy of Enbrel administered by the Sofusa Lymphatic Delivery System for the treatment of Rheumatoid Arthritis.

05:25 EDT ObsEva announces final results from PRIMROSE 1 clinical study of Yselty - ObsEva announced final 76-week results from the PRIMROSE 1 clinical study of Yselty, in development for the treatment of women with heavy menstrual bleeding due to uterine fibroids. These results mark the final data measuring point for both the Phase 3 PRIMROSE 1 and PRIMROSE 2 studies. The PRIMROSE 1 and PRIMROSE 2 trials evaluated 100 mg and 200 mg doses with and without ABT. If approved, Yselty will be the only GnRH antagonist with flexible dose options that addresses the needs of three distinct groups of women suffering from uterine fibroids: 100 mg once daily for women with a contraindication to, or preference to avoid, hormonal ABT, 200 mg once daily with concomitant ABT for long-term use and 200 mg once daily for short-term use. The PRIMROSE 1 post-treatment results are consistent with findings from the PRIMROSE 2 study, showing that off-treatment pain scores remained lower than baseline across all treatment arms. Improvements in other clinically relevant secondary endpoints, including hemoglobin levels and quality of life also persisted off-treatment, supporting the durability of the treatment effect of Yselty. Furthermore, as observed in PRIMROSE 2, the PRIMROSE 1 DXA results at Week 76 showed evidence of BMD recovery for patients treated with both the 100 mg and 200 mg+ ABT doses.

05:20 EDT Liberty Global, Telefonica announce final approval of Virgin Media-O2 JV - The UK's Competition & Markets Authority, or CMA, announced its final approval of the 50:50 joint venture, or JV, between Liberty Global (LBTYA) and Telefonica (TEF) to combine Virgin Media and O2. The CMA cleared the transaction without remedies and now all regulatory conditions are met in alignment with the original terms and the transaction is now expected to close by June 1. Liberty Global and Telefonica announced the joint venture last May, bringing together Virgin Media and O2. The joint venture is expected to deliver synergies valued at EUR 6.2B on a net present value basis after integration costs and will create a nationwide integrated communications provider with EUR 11B of revenue. Liberty Global and Telefonica announced last month the appointment of Lutz Schuler as CEO and Patricia Cobian as CFO of the combined company upon completion of the transaction. Schuler is currently CEO of Virgin Media and Cobian is CFO at O2.

05:09 EDT Jacobs Engineering announces agreement to expand role at Hinkley Point C - Jacobs has signed a partnership agreement with NNB Generation, which is building the Hinkley Point C nuclear power station in Somerset, U.K. The agreement outlines that Jacobs will remain a strategic partner on the $30B project until the station is commissioned and confirms Jacobs' status as a preferred supplier in agreed areas of scope and support. It is the first time that NNB Genco, majority owned by Electricite de France, has signed a partnership agreement with a professional services provider and it paves the way for similar agreements for HPC and its wider supply chain. Jacobs has been closely involved with the Hinkley Point C project since the outset, and will continue supporting licensing and permitting applications to U.K. regulators and acting as delivery partner for program, project and construction management services on the earthworks, main civil works, marine works and heat sink systems. Jacobs also provides a broad range of specialist engineering and technical services, including equipment qualification for IT and telecommunications systems, HVAC dampers, sensors, thermocouples, polar crane, and smart devices and their associated software. Jacobs' Inspection Validation Centre in Warrington, U.K. is the project's sole supplier of independent assessment and assurance for all aspects of non-destructive testing inspection qualification.